Bob Temple, who is widely viewed as an important overseer of regulatory matters, has been asked to give up his role as the acting director of the FDA’s Office of Drug Evaluation 1, so that he can devote more attention to his other position, which is Deputy Center Director for Clinical Science, a job that he assumed in November 2009. “As Deputy Center Director for Clinical Science, Bob has played and continues to play a major role in directing and executing many cross-cutting CDER functions, which enhance the quality and consistency of our operations,” says Janet Woodcock, who heads the FDA Center for Drug Evaluation and Research, in a statement. “Now, he will have more time to further provide valuable regulatory input and methodological assistance across the center.”
